16d
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 data in H2 2026. Read the full analysis here.
Tenax International S.p.A (IT:TNX) has released an update. Tenax International S.p.A. has reported unaudited revenue of €16.4 million for the first nine months of 2024, which is 80% of its total ...
Tonix Pharma ( (TNXP)) has issued an update. Tonix Pharmaceuticals Holding Corp. has unveiled new data from a manuscript showing promising results of its TNX-1700 candidate in cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback